IFM Investors Pty Ltd increased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) by 14.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,788 shares of the medical instruments supplier's stock after buying an additional 1,654 shares during the quarter. IFM Investors Pty Ltd's holdings in West Pharmaceutical Services were worth $3,867,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in WST. BlackRock Inc. lifted its position in West Pharmaceutical Services by 8.9% during the fourth quarter. BlackRock Inc. now owns 8,094,288 shares of the medical instruments supplier's stock worth $3,796,302,000 after buying an additional 664,275 shares during the period. Norges Bank purchased a new position in shares of West Pharmaceutical Services in the 4th quarter worth about $307,506,000. Bank of America Corp DE raised its holdings in shares of West Pharmaceutical Services by 36.7% in the 1st quarter. Bank of America Corp DE now owns 639,632 shares of the medical instruments supplier's stock worth $262,703,000 after purchasing an additional 171,554 shares during the period. Fiera Capital Corp raised its holdings in shares of West Pharmaceutical Services by 3,441.3% in the 1st quarter. Fiera Capital Corp now owns 86,762 shares of the medical instruments supplier's stock worth $35,634,000 after purchasing an additional 84,312 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of West Pharmaceutical Services by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 8,716,312 shares of the medical instruments supplier's stock worth $3,579,876,000 after purchasing an additional 82,459 shares during the period. 91.98% of the stock is currently owned by hedge funds and other institutional investors.
Get
West Pharmaceutical Services alerts:
West Pharmaceutical Services Stock Performance
West Pharmaceutical Services stock opened at $254.24 on Friday. The stock's 50-day moving average is $309.28 and its 200-day moving average is $327.42. The company has a market cap of $18.83 billion, a price-to-earnings ratio of 28.22, a price-to-earnings-growth ratio of 1.03 and a beta of 1.18. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.13 and a quick ratio of 2.41. West Pharmaceutical Services, Inc. has a 12 month low of $248.95 and a 12 month high of $475.00.
West Pharmaceutical Services (NYSE:WST – Get Rating) last released its quarterly earnings data on Thursday, July 28th. The medical instruments supplier reported $2.47 EPS for the quarter, topping analysts' consensus estimates of $2.19 by $0.28. The company had revenue of $771.30 million for the quarter, compared to the consensus estimate of $754.25 million. West Pharmaceutical Services had a return on equity of 29.08% and a net
margin of 23.41%. The company's quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the business posted $2.46 EPS. Equities analysts anticipate that West Pharmaceutical Services, Inc. will post 9.09 earnings per share for the current year.
Insider Transactions at West Pharmaceutical Services
In related news, insider Silji Abraham sold 5,374 shares of the firm's stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $343.93, for a total transaction of $1,848,279.82. Following the sale, the insider now directly owns 3,201 shares in the company, valued at approximately $1,100,919.93. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.60% of the company's stock.
West Pharmaceutical Services Company Profile
(Get Rating)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Read More
- Get a free copy of the StockNews.com research report on West Pharmaceutical Services (WST)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
